4.5 Article

Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells

期刊

ONCOLOGY REPORTS
卷 35, 期 4, 页码 2053-2064

出版社

SPANDIDOS PUBL LTD
DOI: 10.3892/or.2016.4569

关键词

NLRP3 inflammasome; proliferation; migration; lung cancer

类别

资金

  1. National Natural Science Foundation of China (NSFC) [81273571]
  2. National Technological Special Project for 'Significant New Drugs Development' [2011ZX09302-003-02]
  3. Jiangsu Clinical Research Center for Respiratory Diseases project [BL2012012]
  4. Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)

向作者/读者索取更多资源

Lung cancer is the leading cause of cancer death, and it is widely accepted that chronic inflammation is an important risk for the development of lung cancer. Now, it is recognized that the nucleotide-binding and oligomerization domain (NOD) like receptors (NLRs)-containing inflammasomes are involved in cancer-related inflammation. This study was designed to investigate the effects of NLR family pyrin domain containing protein 3 (NLRP3) inflammasome on the proliferation and migration of lung adenocarcinoma cell line A549. Using 5-ethynyl-2'-deoxyuridine (EdU) incorporation assay, scratch assay, and Transwell migration assay, we showed that activation of the NLRP3 inflammasome by LPS+ATP enhanced the proliferation and migration of A549 cells. Western blot analysis showed that activation of phosphorylation of Akt, ERK1/2, CREB and the expression of Snail increased, while the expression of E-cadherin decreased after the activation of NLRP3 inflammasome. Moreover, these effects were inhibited by the following treatments: i) down regulating the expression of NLRP3 by short hairpin RNA (shRNA) interference, ii) inhibiting the activation of NLRP3 inflammasome with a caspase-1 inhibitor, iii) blocking the interleukin-1(beta (IL-1 beta) and IL-18 signal transduction with IL-1 receptor antagonist (IL-1Ra) and IL-18 binding protein (IL-18BP). Collectively, these results indicate that NLRP3 inflammasome plays a vital role in regulating the proliferation and migration of A549 cells and it might be a potential target for the treatment of lung cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Iptakalim inhibits PDGF-BB-induced human airway smooth muscle cells proliferation and migration

Wenrui Liu, Hui Kong, Xiaoning Zeng, Jingjing Wang, Zailiang Wang, Xiaopei Yan, Yanli Wang, Weiping Xie, Hong Wang

EXPERIMENTAL CELL RESEARCH (2015)

Article Oncology

Iptakalim influences the proliferation and apoptosis of human pulmonary artery smooth muscle cells

Qinglin Li, Xiaopei Yan, Hui Kong, Weiping Xie, Hong Wang

MOLECULAR MEDICINE REPORTS (2016)

Article Mycology

Pulmonary Fungal Diseases in Immunocompetent Hosts: A Single-Center Retrospective Analysis of 35 Subjects

XiaoPei Yan, Feng Zong, Hui Kong, YanLi Wang, XinYun Zhao, WenRui Liu, ZaiLiang Wang, WeiPing Xie

MYCOPATHOLOGIA (2016)

Article Oncology

NLRP3 inflammasome inhibition attenuates silica-induced epithelial to mesenchymal transition (EMT) in human bronchial epithelial cells

Xiang Li, Xiaopei Yan, Yanli Wang, Jingjing Wang, Fang Zhou, Hong Wang, Weiping Xie, Hui Kong

EXPERIMENTAL CELL RESEARCH (2018)

Article Health Care Sciences & Services

Metagenomic next-generation sequencing of radial ultrasound bronchoscopy-guided cocktail specimens as an efficient method for the diagnosis of focal pulmonary infections: a randomised study

Ying Chen, Xiaopei Yan, Ning Li, Qin Zhang, Yantian Lv, Ting Ruan

Summary: The study showed that using cocktail specimens for pathogen detection in focal pulmonary infections yielded better results compared to other methods, and the use of antibiotics had minimal impact on the outcomes of mNGS analysis.

ANNALS OF PALLIATIVE MEDICINE (2021)

Article Respiratory System

Epidemiology and risk factors of chronic obstructive pulmonary disease in Suzhou: a population-based cross-sectional study

Xiaopei Yin, Li Xu, Baoyu Shi, Hui Wang, Xiao Xu, Guopeng Xu

JOURNAL OF THORACIC DISEASE (2020)

暂无数据